In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Working Group on Cardiovascular Regenerative and Reparative Medicine

 

ESC-WG-Cardiovascular-Regenerative-Reparative-Medicine-Logo-official.png

The Mission of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine is to improve our knowledge and to develop therapies in this field through the synergy of basic discoveries and translational clinical efforts from dedicated centres all around the world.

 

More about the Working Group



Upcoming Events

  • August 2024
    • ESC Congress 2024
      Friday 30 August
      ESC event
      London - United Kingdom of Great Britain and Northern Ireland

      ESC Congress 2024 is your journey to the heart of cardiology. Be part of the world’s leading cardiovascular congress next August, in London and online. 

      30/08/2024 00:00 02/09/2024 00:00 Europe/Paris ESC Congress 2024

      Access event page

      London - United Kingdom of Great Britain and Northern Ireland European Society of Cardiology congress@escardio.org true DD/MM/YYYY
  • March 2024
    • ESC Working Group on Cardiovascular Regenerative and Reparative Medicine
      Tuesday 12 March
      ESC event

      Nucleotide and in particular RNA-therapeutics are of increasing importance. With Inclisiran (PMID: 27959715), we have a first small interfering RNA (siRNA) therapeutic for the blocking of PCSK9 translation in clinical practice for lowing of LDL-cholesterol. More recently, CRISPR Cas9 encoding RNA with concomitant single guide RNA targeting misfolded transthyretin (TTR) has demonstrated clinical efficacy in patients with TTR amyloidosis (PMID: 34215024). Numerous RNA therapeutics will follow (PMID: 36329321; PMID: 33816449), riding also on the clinical experienced gained from modRNA development for COVID vaccination, because they are easy to develop and can be precisely targeted as highly specific therapies.

      12/03/2024 15:30 12/03/2024 16:30 Europe/Paris Working Group Talk "RNA-based therapies"

      Access event page

      ESC Working Group on Cardiovascular Regenerative and Reparative Medicine contact@escardio.org DD/MM/YYYY